Current Report Filing (8-k)
16 Novembre 2022 - 10:16PM
Edgar (US Regulatory)
0001174940
false
0001174940
2022-11-16
2022-11-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934.
Date
of Report: November 16, 2022
(Date
of earliest event reported)
Oragenics,
Inc.
(Exact
name of registrant as specified in its charter)
FL |
|
001-32188 |
|
59-3410522 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
Number) |
4902
Eisenhower Boulevard, Suite
125 Tampa, FL |
|
33634 |
(Address
of principal executive offices) |
|
(Zip
Code) |
813-286-7900
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock |
|
OGEN |
|
NYSE
American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
November 16, 2022, Michael Sullivan, the Chief Financial Officer of Oragenics (the “Company”) notified the Company that he
would be resigning from the Company, effective December 14, 2022, to pursue other opportunities. Mr. Sullivan has agreed to stay through
such date in order to facilitate a smooth and orderly transition of his duties and responsibilities.
The
Company expects to promptly begin a search for Mr. Sullivan’s successor.
Mr.
Sullivan’s resignation was not due to any disagreement with the Company or its Board of Directors on any matter related to its
operations, policies or practices.
Item
9.01 Financial Statements and Exhibits.
Exhibit
No. |
|
Description |
|
|
|
|
|
104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
In
accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized on this 16th day of November, 2022.
|
ORAGENICS,
INC.
(Registrant)
|
|
|
|
BY: |
/s/
Kimberly Murphy |
|
|
Kimberly
Murphy
President
and Chief Executive Officer
|
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024